New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
12:39 EDTHALO, BAXFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
The panel voted 15-1 that the drug from Baxter (BAX) and Halozyme (HALO) has a favorable risk/benefit in treatment of primary immune deficiency disorders, according to Bloomberg.
News For BAX;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:34 EDTHALOHalozyme receives EU Orphan Drug designation for PEGPH20
Subscribe for More Information
December 17, 2014
09:13 EDTHALOHalozyme up nearly 5% after announcing collaboration pact with Janssen
Subscribe for More Information
09:04 EDTHALOHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
09:02 EDTHALOHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
December 15, 2014
09:03 EDTBAXBaxter to divest Vero cell vaccines platform to Nanotherapeutics
Baxter International (BAX) announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial details were not disclosed. The agreement with Nanotherapeutics includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus. In recent weeks, the company has also completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer (PFE).
December 10, 2014
17:19 EDTBAXBaxter announces filing of Form 10 in connection with planned spin-off
Subscribe for More Information
December 9, 2014
12:22 EDTBAXPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use